CN107427510A - 普那布林联合免疫检查点抑制剂的用途 - Google Patents

普那布林联合免疫检查点抑制剂的用途 Download PDF

Info

Publication number
CN107427510A
CN107427510A CN201680015268.XA CN201680015268A CN107427510A CN 107427510 A CN107427510 A CN 107427510A CN 201680015268 A CN201680015268 A CN 201680015268A CN 107427510 A CN107427510 A CN 107427510A
Authority
CN
China
Prior art keywords
inhibitor
test point
immunologic test
cancer
point inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680015268.XA
Other languages
English (en)
Chinese (zh)
Inventor
黄岚
李自宜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Priority to CN202311274843.6A priority Critical patent/CN117100753A/zh
Publication of CN107427510A publication Critical patent/CN107427510A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680015268.XA 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途 Pending CN107427510A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311274843.6A CN117100753A (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US62/115,468 2015-02-12
US201562255259P 2015-11-13 2015-11-13
US62/255,259 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311274843.6A Division CN117100753A (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途

Publications (1)

Publication Number Publication Date
CN107427510A true CN107427510A (zh) 2017-12-01

Family

ID=56615698

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680015268.XA Pending CN107427510A (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途
CN202311274843.6A Pending CN117100753A (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311274843.6A Pending CN117100753A (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途

Country Status (16)

Country Link
US (1) US20180028531A1 (https=)
EP (1) EP3256130A4 (https=)
JP (4) JP7243021B2 (https=)
KR (2) KR20170117113A (https=)
CN (2) CN107427510A (https=)
AU (3) AU2016219204B2 (https=)
CA (1) CA2975729A1 (https=)
CL (1) CL2017002050A1 (https=)
HK (1) HK1247816A1 (https=)
IL (2) IL286282B2 (https=)
MX (2) MX394865B (https=)
MY (1) MY193968A (https=)
NZ (1) NZ734256A (https=)
RU (1) RU2723021C2 (https=)
SG (1) SG11201706281YA (https=)
WO (1) WO2016130839A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524442A (zh) * 2018-06-05 2018-09-14 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
CN112135614A (zh) * 2018-01-24 2020-12-25 大连万春布林医药有限公司 通过施用普那布林减少血小板减少症的组合物和方法
CN112638388A (zh) * 2018-08-16 2021-04-09 大连万春布林医药有限公司 刺激免疫反应的方法和组合物
CN112778155A (zh) * 2019-11-11 2021-05-11 万春药业公司 妥卡雷琐衍生物及其用途
CN112955162A (zh) * 2018-11-01 2021-06-11 北卡罗莱纳州立大学 脂肪细胞介导的抗癌治疗剂的递送
CN113456643A (zh) * 2021-08-11 2021-10-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN113891714A (zh) * 2020-05-04 2022-01-04 大连万春布林医药有限公司 增强低免疫原性癌症中癌细胞杀伤的三联疗法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗脑肿瘤的方法
AU2016275574B2 (en) * 2015-06-11 2019-07-11 Bionomics Limited Pharmaceutical combination and uses thereof
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
EP3505183B1 (en) * 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
BR112019007145A2 (pt) * 2016-10-14 2019-07-02 Eisai R&D Man Co Ltd combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
AU2018236168B2 (en) * 2017-03-13 2024-02-29 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
CN110913856A (zh) * 2017-07-26 2020-03-24 株式会社钟根堂 包含血管破坏剂及免疫检查点抑制剂的用于预防或治疗癌症的组合物
AU2018328773B2 (en) * 2017-09-08 2023-11-16 University Health Network Combination therapies for inhibition of Polo-like Kinase 4
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
ES3060133T3 (en) * 2018-06-01 2026-03-25 Beyondspring Pharmaceuticals Inc Composition and method of treating cancer associated with egfr mutation
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
WO2024191805A1 (en) * 2023-03-10 2024-09-19 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
CN100540548C (zh) * 2002-08-02 2009-09-16 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711487A1 (en) * 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2010045580A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
US20110160159A1 (en) * 2009-09-15 2011-06-30 John Ryan Treatment of cancer
EP2571577A1 (en) * 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20150004175A1 (en) * 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
JP6457940B2 (ja) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
EP2958571B1 (en) * 2013-02-21 2024-04-10 Michele Maio Dna hypomethylating agents for cancer therapy
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
SG11201509742QA (en) * 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
JP6411523B2 (ja) * 2013-10-11 2018-10-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
WO2017139231A1 (en) * 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100540548C (zh) * 2002-08-02 2009-09-16 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOTTE B.BERTELSEN: "Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation", 《INTERNATIONAL JOURNAL OF RADIATION BIOLOGY》 *
无: "微管蛋白聚合抑制类抗肿瘤药Plinabulin", 《药学进展》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135614A (zh) * 2018-01-24 2020-12-25 大连万春布林医药有限公司 通过施用普那布林减少血小板减少症的组合物和方法
CN108524442A (zh) * 2018-06-05 2018-09-14 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
CN112638388A (zh) * 2018-08-16 2021-04-09 大连万春布林医药有限公司 刺激免疫反应的方法和组合物
CN112955162A (zh) * 2018-11-01 2021-06-11 北卡罗莱纳州立大学 脂肪细胞介导的抗癌治疗剂的递送
CN112955162B (zh) * 2018-11-01 2023-10-13 北卡罗莱纳州立大学 脂肪细胞介导的抗癌治疗剂的递送
CN112778155A (zh) * 2019-11-11 2021-05-11 万春药业公司 妥卡雷琐衍生物及其用途
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
CN113891714A (zh) * 2020-05-04 2022-01-04 大连万春布林医药有限公司 增强低免疫原性癌症中癌细胞杀伤的三联疗法
CN113456643A (zh) * 2021-08-11 2021-10-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用

Also Published As

Publication number Publication date
KR20170117113A (ko) 2017-10-20
MX2022007472A (es) 2022-06-29
AU2016219204B2 (en) 2021-01-21
JP7157181B2 (ja) 2022-10-19
AU2016219204A1 (en) 2017-08-24
RU2017127966A3 (https=) 2019-06-20
IL253784B (en) 2021-09-30
JP7564172B2 (ja) 2024-10-08
MX2017010338A (es) 2017-12-20
CL2017002050A1 (es) 2018-04-13
AU2024200672A1 (en) 2024-02-22
JP7243021B2 (ja) 2023-03-22
IL253784A0 (en) 2017-09-28
SG11201706281YA (en) 2017-09-28
KR20240110996A (ko) 2024-07-16
JP2018508572A (ja) 2018-03-29
NZ750444A (en) 2021-03-26
RU2017127966A (ru) 2019-03-12
EP3256130A1 (en) 2017-12-20
EP3256130A4 (en) 2018-08-01
JP2021050247A (ja) 2021-04-01
IL286282B2 (en) 2023-10-01
BR112017016902A2 (pt) 2018-03-27
AU2021202416B2 (en) 2024-02-15
AU2021202416A1 (en) 2021-05-20
US20180028531A1 (en) 2018-02-01
WO2016130839A1 (en) 2016-08-18
IL286282A (en) 2021-10-31
NZ734256A (en) 2019-02-22
HK1247816A1 (zh) 2018-10-05
IL286282B1 (en) 2023-06-01
MY193968A (en) 2022-11-03
RU2723021C2 (ru) 2020-06-08
AU2024200672B2 (en) 2026-03-05
CA2975729A1 (en) 2016-08-18
MX394865B (es) 2025-03-24
JP2024174070A (ja) 2024-12-13
JP2022190005A (ja) 2022-12-22
CN117100753A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
JP7564172B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
US11857522B2 (en) Compositions containing tucaresol or its analogs
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
TW202304442A (zh) 用於治療腫瘤的治療組成物和方法
CN112135639A (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
HK40099485A (zh) 普那布林联合免疫检查点抑制剂的用途
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
TW202315631A (zh) 增強低免疫原性癌症中癌細胞毒殺的三聯療法
HK40102238A (zh) 用於治疗肿瘤的治疗组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247816

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190806

Address after: No. 19-6 ShuangD Port and ShuangD4 Street, Dalian Economic and Technological Development Zone, Liaoning Province

Applicant after: BEYONDSPRING PHARMACEUTICALS, Inc.

Address before: American New York

Applicant before: BEYONDSPRING PHARMACEUTICALS Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20171201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247816

Country of ref document: HK